Published on 24/12/2025
Leveraging External Controls and Historical Data in Rare Disease Clinical Trials
Introduction: Addressing Comparator Challenges in Rare Diseases
One of the most pressing challenges in designing clinical trials for rare and ultra-rare diseases is the difficulty in recruiting sufficient participants for randomized control arms. The ethical dilemma of assigning patients to a placebo group in life-threatening or progressive diseases further complicates trial design. In response, researchers and sponsors are increasingly turning to external control arms and historical data as viable alternatives to traditional comparators.
This article outlines the rationale, methods, regulatory expectations, and case examples surrounding the use of external controls in rare disease trials. Properly implemented, these strategies can significantly enhance trial feasibility, reduce ethical burden, and accelerate drug development.
What Are External Controls and How Are They Used?
External controls refer to patient-level or aggregated data derived outside the current trial to serve as a comparator group. This can include:
- Historical controls: Data from prior studies with similar eligibility criteria
- Real-world evidence (RWE): Data from disease registries, electronic health records (EHR), or observational cohorts
- Synthetic control arms: Constructed using matched patient populations from multiple data sources
These controls are particularly valuable when the
Statistical Approaches to Enhance Validity
To ensure that comparisons with external controls are scientifically valid, sponsors must mitigate bias and confounding. Techniques include:
- Propensity score matching (PSM): Balances baseline characteristics
- Bayesian hierarchical modeling: Incorporates prior and current evidence dynamically
- Covariate adjustment: Uses regression models to account for differences
- Time-to-event matching: Aligns survival curves or disease progression
For instance, if survival is the endpoint, Kaplan-Meier curves from historical data can be aligned with those from the investigational group and compared using log-rank or Bayesian survival models. These techniques are recognized in regulatory settings provided the assumptions are clearly stated and sensitivity analyses are conducted.
Regulatory Acceptance and Requirements
Both FDA and EMA acknowledge the role of external controls in rare disease trials:
- FDA: “Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products” (2023 draft guidance) explicitly allows historical controls in certain contexts, especially for life-threatening diseases.
- EMA: Encourages the use of real-world data in orphan indications, provided the sources are robust and well-documented.
- PMDA (Japan): Supports historical controls if the trial context makes randomization impractical.
Visit Japan’s RCT Portal to review regulatory pathways using external data in rare indications.
Case Example: External Controls in Batten Disease Gene Therapy
An illustrative example comes from the development of a gene therapy for CLN2 Batten disease, a fatal pediatric neurodegenerative condition. Due to the ultra-rare nature of the disease, a traditional randomized controlled trial (RCT) was not feasible. Instead, researchers conducted a single-arm study with 23 participants and used a historical cohort of untreated patients from a disease registry as the comparator.
Outcome metrics included:
- Motor and language composite scores measured every 6 months
- Rate of decline was compared to historical natural history data
Results showed statistically significant slowing of disease progression, and the therapy received Accelerated Approval from the FDA and Conditional Marketing Authorization from EMA. The regulators accepted the justification for using historical controls given the unmet need, rarity, and ethical considerations.
Ethical Justifications and Limitations
The use of external controls must be balanced with ethical and scientific considerations. Benefits include:
- Minimized patient risk from placebo assignment
- Faster recruitment as no randomization is required
- Enhanced generalizability when real-world cohorts are diverse
However, limitations persist:
- Selection bias if external data are not comparable
- Data quality concerns in retrospective datasets
- Regulatory caution around non-concurrent comparators
Therefore, external control strategies must be planned with rigorous methodology, transparent reporting, and sensitivity analyses to test robustness of findings.
Design Considerations for Sponsors
To build a credible external control arm, sponsors should consider:
- Eligibility alignment: Ensure inclusion/exclusion criteria match between arms
- Endpoint harmonization: Use the same clinical outcome assessments and timing
- Temporal consistency: Avoid data from outdated medical practice periods
- Source verification: Use validated disease registries or curated RWD
It is also advisable to pre-specify external control plans in the protocol and seek advice through regulatory scientific advice or Type B meetings.
When to Avoid External Controls
While promising, external control arms are not suitable for all scenarios. They should generally be avoided when:
- There is high variability in disease presentation or progression
- No reliable historical or real-world datasets exist
- Primary endpoints are subjective or poorly documented in prior studies
- Randomized design is still feasible within timelines
In such cases, a randomized or hybrid design with limited placebo exposure may be more appropriate.
Conclusion: A Transformational Tool for Rare Disease Trials
External control arms and historical data offer a lifeline for developers of rare disease therapies facing recruitment and ethical hurdles. When designed and executed with rigor, these approaches can unlock faster pathways to approval, reduce patient burden, and fulfill urgent unmet needs.
They are not a shortcut but a strategic option that, when used responsibly and transparently, aligns scientific validity with patient-centric innovation. As regulatory frameworks evolve to embrace real-world evidence and flexible designs, the role of external comparators in rare disease trials will only grow in importance.